Literature DB >> 33328720

Evaluation of Metabolic Monitoring and Diabetes Incidence in the First Year for Veterans Newly Started on an Atypical Antipsychotic.

Clayton Hamilton1, Janice Taylor1, Scott Mambourg1.   

Abstract

PURPOSE: This retrospective chart review is an evaluation of patient and health care provider adherence to a metabolic monitoring protocol as well as progression to type 2 diabetes mellitus (T2DM) in the first year after atypical antipsychotic initiation.
METHODS: Patient (N = 1,651) data from February 2014 to February 2019 were collected from the US Department of Veterans Affairs (VA) Corporate Data Warehouse for 8 VA medical centers within Veterans Integrated Service Network (VISN) 21. Collected data included patient demographic, laboratory results, and medication history.
RESULTS: In the final cohort, 6% of patients were found to have progressed to T2DM. Adherence to appropriate metabolic monitoring was found to be overall suboptimal.
CONCLUSIONS: The findings of this project demonstrate that patients in VISN 21 who were previously antipsychotic-naïve and nondiabetic may be at increased risk of progression to T2DM when compared with the general population. To effectively manage patient risk, health care providers and patients should improve adherence to metabolic monitoring.
Copyright © 2020 Frontline Medical Communications Inc., Parsippany, NJ, USA.

Entities:  

Year:  2020        PMID: 33328720      PMCID: PMC7735454          DOI: 10.12788/fp.0067

Source DB:  PubMed          Journal:  Fed Pract        ISSN: 1078-4497


  6 in total

Review 1.  Consensus development conference on antipsychotic drugs and obesity and diabetes.

Authors: 
Journal:  Diabetes Care       Date:  2004-02       Impact factor: 19.112

2.  Endogenous and Antipsychotic-Related Risks for Diabetes Mellitus in Young People With Schizophrenia: A Danish Population-Based Cohort Study.

Authors:  Anto P Rajkumar; Henriette Thisted Horsdal; Theresa Wimberley; Dan Cohen; Ole Mors; Anders D Børglum; Christiane Gasse
Journal:  Am J Psychiatry       Date:  2017-01-20       Impact factor: 18.112

3.  A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls.

Authors:  Donald C Goff; Lisa M Sullivan; Joseph P McEvoy; Jonathan M Meyer; Henry A Nasrallah; Gail L Daumit; Steven Lamberti; Ralph B D'Agostino; Thomas S Stroup; Sonia Davis; Jeffrey A Lieberman
Journal:  Schizophr Res       Date:  2005-09-28       Impact factor: 4.939

4.  Metabolic testing rates in 3 state Medicaid programs after FDA warnings and ADA/APA recommendations for second-generation antipsychotic drugs.

Authors:  Elaine H Morrato; Benjamin Druss; Daniel M Hartung; Robert J Valuck; Richard Allen; Elizabeth Campagna; John W Newcomer
Journal:  Arch Gen Psychiatry       Date:  2010-01

5.  Monitoring veterans for metabolic side effects when prescribing antipsychotics.

Authors:  Dinesh Mittal; Chenghui Li; James Silas Williams; Kristen Viverito; Reid D Landes; Richard R Owen
Journal:  Psychiatr Serv       Date:  2013-01       Impact factor: 3.084

6.  Economic costs of diabetes in the U.S. in 2012.

Authors: 
Journal:  Diabetes Care       Date:  2013-03-06       Impact factor: 19.112

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.